Uses of POMC-specific antibody and marchf6
Antibodies targeting POMC and utilizing MARCHF6 to degrade and translocate POMC address the metabolic disorders associated with POMC accumulation, effectively treating metabolic diseases by reducing ER stress and ferroptosis, improving metabolic health.
Patent Information
- Application Number
- PCT/KR2024/007779
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-10-06
- Filing Date
- 2024-06-07
- Publication Date
- 2024-12-12
AI Technical Summary
Metabolic diseases such as obesity and diabetes are increasingly prevalent due to dietary changes and imbalances, particularly caused by westernization of diets, leading to POMC accumulation in cytoplasmic neurons, which induces ER stress and ferroptosis, and current treatments are ineffective in addressing these underlying metabolic disorders.
Development of antibodies specific for POMC and the use of MARCHF6 to recognize and degrade POMC, promoting its translocation to the ER, thereby reducing ER stress and ferroptosis, and using these antibodies or fragments in pharmaceutical compositions for diagnosis and treatment of metabolic diseases.
The specific antibodies and MARCHF6-based compositions effectively diagnose and treat metabolic diseases by reducing POMC accumulation, alleviating ER stress and ferroptosis, thereby improving metabolic homeostasis and preventing conditions like obesity and diabetes.
Smart Images

Figure KR2024007779_12122024_PF_FP_ABST
Abstract
Description
Antibodies specific for POMC and the use of MARCHF6
[0001] The present invention relates to antibodies specific for POMC, particularly antibodies specific for POMC remaining in the cytoplasm, and their uses, and to the use of Marchf6 in the treatment of metabolic diseases.
[0002] Metabolic diseases are a general term for diseases caused by metabolic disorders in the body. They are generally caused by imbalances in carbohydrates, lipids, proteins, vitamins, electrolytes, and water. Examples include obesity, diabetes, hyperlipidemia, arteriosclerosis, fatty liver, and hypertension. Metabolic diseases are also called lifestyle diseases because the imbalance of energy metabolism in the body due to a high-calorie, high-fat, and high-carbohydrate diet can lead to obesity, insulin resistance, and metabolic inflammation, which can cause lipid metabolic disorders and degenerative diseases such as type 2 diabetes. Recently, in Korea, the incidence of chronic degenerative diseases such as hypertension, heart disease, arteriosclerosis, and diabetes has increased due to changes in dietary habits such as an increase in the intake of processed foods and animal products and a decrease in the intake of plant-based foods due to the westernization of the diet.
[0003] Obesity (commonly defined as a body mass index of approximately >30 kg / m2) is a type of metabolic disease caused by an imbalance between caloric intake and expenditure, and is often associated with various pathological conditions such as hyperinsulinemia, insulin resistance, diabetes, hypertension, and dyslipidemia (Mantzoros et al, J Clin Endocrinol Metab, 85:4000-2, 2000). As the incidence of obesity has rapidly increased over the past several decades, interest in obesity has continued to grow. It is known that the cause of obesity is that excessive energy supply causes an increase in the size and number of fat cells, which are then accumulated as body fat. In addition, various causes are known to be at play, such as genetic factors, environmental factors due to a Westernized diet, psychological factors, and energy metabolism abnormalities. If this state of obesity persists for a long time, it not only causes discomfort in physical activity, decreased work efficiency, and abnormal growth, but also causes various diseases such as diabetes, hyperlipidemia, elevated blood cholesterol, kidney disease, heart disease, stroke, arteriosclerosis, fatty liver disease, coronary artery disease, and joint disease.
[0004] Many organs / tissues have been implicated in the development of obesity and type 2 diabetes, and the hypothalamus in particular has been recognized as a key player in energy homeostasis, including the control of energy intake (Stellar, Psychol Rev 61:5-22, 1954). The hypothalamus regulates body weight by precisely balancing food intake, energy expenditure, and body fat mass. The primary hypothalamic regions involved in energy regulation (which, when impaired, lead to hypothalamic obesity) include the ventromedial hypothalamus, paraventricular nucleus, arcuate nucleus, and lateral hypothalamic area. Additionally, signals from adipose tissue mass within the body (including leptin) and from the gastrointestinal tract (including GLP-1, PYY, and / or pancreatic insulin / aminin) influence the hypothalamus centrally. Disorders that interact with the hypothalamus, or that involve damage to the hypothalamus, can lead to pathological hypothalamic obesity. Weight gain due to hypothalamic obesity results from a disruption of the normal homeostatic function of the hypothalamus, with loss of control of satiety and hunger, inability to regulate energy balance and / or decreased energy expenditure, and / or frequent progression to hyperinsulinemia and diabetes. Unlike the weight gain seen in normal obesity, obesity resulting from hypothalamic dysfunction and failure to regulate feeding results in compulsive overeating that is difficult to tolerate and typically unresponsive to diet and exercise. Such hypothalamic obesity can be caused by any damage or defect in the hypothalamus.Hypothalamic obesity can be caused by genetic syndromes, such as mutations in leptin or leptin receptors, CART (cocaine and amphetamine-related transcript), POMC (proopiomelanocortin), prohormone convertase, MC4R (melanocortin-4 receptor), singleminded 1 (a transcription factor essential for the formation of the supraoptic nucleus and PVN nuclei in the hypothalamus), or TrkB, as well as Prader-Willi syndrome and Bardet-Biddle syndrome (BBS), which are caused by deletions of paternally imprinted genes on chromosome 15q11-q13.
[0005] The purpose of the present invention is to provide an antigen peptide for producing an antibody specific to POMC (pro-opiomelanocortin).
[0006] In addition, it is an object of the present invention to provide a composition for producing an antibody specific to POMC.
[0007] In addition, it is an object of the present invention to provide a method for producing an antibody specific for POMC.
[0008] It is also an object of the present invention to provide an antibody or antigen-binding fragment specific for POMC.
[0009] In addition, it is an object of the present invention to provide a pharmaceutical composition for preventing or treating a disease associated with POMC accumulation.
[0010] In addition, it is an object of the present invention to provide a pharmaceutical composition for preventing or treating a disease related to Marchf6 dysfunction.
[0011] In addition, it is an object of the present invention to provide a method for providing information for diagnosing metabolic diseases.
[0012] In addition, it is an object of the present invention to provide a pharmaceutical composition for preventing or treating metabolic diseases.
[0013] In addition, it is an object of the present invention to provide a composition for promoting POMC decomposition.
[0014] In addition, it is an object of the present invention to provide a composition for promoting movement to the ER.
[0015] In addition, it is an object of the present invention to provide a composition for inhibiting ER stress or ferroptosis.
[0016] In addition, an object of the present invention is to provide a food composition for preventing or improving metabolic diseases.
[0017] In addition, it is an object of the present invention to provide a method for screening for an obesity treatment agent.
[0018] To achieve the above purpose, the present invention provides an antigen peptide for producing an antibody specific to POMC (pro-opiomelanocortin).
[0019] Additionally, the present invention provides a composition for producing an antibody specific to POMC.
[0020] In addition, the present invention provides a method for producing an antibody specific for POMC.
[0021] Additionally, the present invention provides an antibody or antigen-binding fragment specific for POMC.
[0022] In addition, the present invention provides a pharmaceutical composition for preventing or treating a disease associated with POMC accumulation.
[0023] In addition, the present invention provides a pharmaceutical composition for preventing or treating a disease related to Marchf6 dysfunction.
[0024] In addition, the present invention provides a method for providing information for diagnosing metabolic diseases.
[0025] In addition, the present invention provides a pharmaceutical composition for preventing or treating metabolic diseases.
[0026] In addition, the present invention provides a composition for promoting POMC decomposition.
[0027] Additionally, the present invention provides a composition for promoting movement to the ER.
[0028] Additionally, the present invention provides a composition for inhibiting ER stress or ferroptosis.
[0029] In addition, the present invention provides a food composition for preventing or improving metabolic diseases.
[0030] In addition, the present invention provides a method for screening for an obesity treatment agent.
[0031] In the present invention, it was revealed that Marchf6 directly recognizes POMC, an appetite-regulating hormone precursor protein, and regulates its degradation and movement to the ER, thereby regulating ER stress and ferroptosis caused by POMC accumulation in the cytoplasm, and the specific mechanism thereof was confirmed. In particular, it was confirmed in vivo that deficiency of Marchf6 in POMC neurons causes metabolic disorders such as obesity, binge eating, increased appetite, and decreased energy metabolism, and therefore, it can be usefully utilized for the prevention or treatment of metabolic diseases including obesity.
[0032] In addition, the present invention reveals that cytoplasmic accumulation of POMC, an appetite-regulating hormone precursor protein, induces ER stress and ferroptosis, and that Marchf6 directly binds to it, degrades it, and moves it to the ER. In addition, by producing a POMC-specific antibody that remains in the cytoplasm, it was confirmed that POMC that actually accumulates in the cytoplasm of POMC neurons can be specifically detected. Therefore, this can be usefully utilized for the diagnosis and treatment of diseases related to POMC accumulation or Marchf6 dysfunction.
[0033] Figure 1 is a diagram showing the screening of Marchf6 binding proteins:
[0034] A: Screening experiment process;
[0035] B: Putative domain-specific binding protein of Marchf6; and
[0036] C: Split-Ub analysis using Marchf6 in the battlefield as bait and POMC, Bnip3, Gps1, SNAPIN, Yif1a, Hspa5, Hax1, Fhl2, and Mcfd2 as prey.
[0037] Figure 2 is a diagram exploring the interaction sites of Marchf6 and POMC:
[0038] A: Schematic diagram and sequence of Marchf6;
[0039] B: Y2H analysis;
[0040] C: Split-Ub analysis;
[0041] D and E: Reciprocal co-immunoprecipitation of Marchf63f or Marchf63f P460A and POMCha (*: nonspecific band);
[0042] F: CHX-trace analysis of POMC and SM;
[0043] G: Immunoblotting of POMCha and Marchf63f; and
[0044] H: In vivo ubiquitination analysis of POMCmyc under MG132 (10 μM) treatment for 8 h.
[0045] Figure 3 is a diagram analyzing the POMC degradation mechanism of Marchf6:
[0046] A: Immunoblotting of endogenous Marchf6;
[0047] B: POMC ha CHX-trace analysis of;
[0048] C: CHX-trace analysis of endogenous POMC;
[0049] D: POMC under MG132 (10 μM) treatment for 8 hours myc In vivo ubiquitination analysis of;
[0050] E: POMC after treatment with Bag6, Derl1, or VCP siRNA haCHX-trace analysis; and
[0051] F: POMC after treatment with Bag6, Derl1, or VCP siRNA ha Relative mRNA levels of .
[0052] Figure 4 is a diagram confirming the POMC recognition site of Marchf6:
[0053] A: Y2H analysis (left) and composition of POMC (right);
[0054] SP: signal peptide;
[0055] N-POMC: Nt-POMC domain;
[0056] ACTH: adrenocorticotropic hormone;
[0057] β-LPH: β-lipotropin;
[0058] B: Split-Ub analysis using Marchf6 as bait and POMC fragment as prey;
[0059] C: GST pulldown analysis;
[0060] D: Antibodies to POMC containing SP (anti-POMC SP ) Epitope for production
[0061] outline;
[0062] E: anti-POMC SP GST-POMC 1-76 , GST-POMC 27-76 and GST-POMC 1-26 Immunoblotting of;
[0063] F: IP and IB experiments after digitonin / Triton X-100-based cytosol-organelle fractionation
[0064] Schematic diagram; and
[0065] G: anti-POMC after digitonin / Triton X-100-based cytosol-organelle fractionation SPIP using and IB using anti-ha results.
[0066] Figure 5 is a diagram showing the ER stress and ferroptosis inhibition effect of Marchf6 by POMC:
[0067] A: POMC ha Lipid ROS levels increased with progressive expression;
[0068] B: POMC ha Relative NADP(H) levels with progressive increase in expression;
[0069] C: POMC ha Relative cell viability with progressive increase in expression;
[0070] D: POMC ha Relative LDH release with progressive increase in expression;
[0071] E: POMC ha Immunoblotting of Gpx4, CHOP, Nox2 and Nox4 with progressive increase in expression;
[0072] F: Immunoblotting of 4-HNE, Gpx4, CHOP, Nox2, and Nox4 with or without 24-h treatment with Fer-1 (5 μM);
[0073] G: Lipid ROS levels;
[0074] H: relative cell viability;
[0075] I: Immunoblotting of Gpx4, CHOP, Nox2, and Nox4; and
[0076] J: Relative cell viability in the presence of Fer-1 (5 μM), Z-VAD (20 μM), or Nec-1 (40 μM).
[0077] Figure 6 is a diagram analyzing the mechanism by which cytoplasmic POMC induces ER stress and ferroptosis:
[0078] A: Lipid ROS levels;
[0079] B to D: NADP(H) levels, cell viability, and LDH release;
[0080] E: Immunoblotting of Gpx4, CHOP, Nox2, Nox4, Atf4, eIF2α-p (phosphorylated eIF2α), eIF2α, PERK-p (phosphorylated PERK), PERK, Ire1-p (phosphorylated Ire1), Ire1, and Atf6;
[0081] F: Relative Gpx4 mRNA levels;
[0082] G: CHX-trace analysis of Gpx4;
[0083] H: Immunoblotting of Gpx4 in cells treated with MG132 (20 μM), 3-MA (5 mM), BafA1 (100 nM), or CQ (50 μM) for 8 h;
[0084] I: Schematic representation of predicted cytoplasmic POMC-induced Gpx4 degradation via CMA;
[0085] J: Immunoblotting of Hsp90, Hsc70, and Lamp2a; and
[0086] K: CHX-tracing analysis of Gpx4 after siRNA treatment against Lamp2a.
[0087] Figure 7 is a diagram analyzing the inhibition of Hspa5-Gpx4 interaction by cytoplasmic POMC:
[0088] A: CHX-trace analysis of Gpx4;
[0089] B: Gpx4 mRNA level;
[0090] C: Hspa5, Gpx4, tubulin (cytoplasmic marker), calreticulin (ER lumen marker), Sec61α (ER membrane marker) and Na after digitonin / Triton X-100-based cytosolic / organelle fractionation + / K + Immunoblotting of ATPase (plasma membrane marker);
[0091] D: POMC ha Δ1-26 and Hspa5 myc Mutual co-immunoprecipitation analysis of;
[0092] E: Hspa5 myc Immunoprecipitation of Gpx4 using;
[0093] F: Anti-Hspa5 antibody was used with or without Fer-1 (5 μM) treatment for 24 hours.
[0094] Immunoprecipitation of Gpx4;
[0095] G: Anti-POMC after digitonin / Triton X-100-based cytosol / organelle fractionation with or without Fer-1 (5 μM) treatment SP Co-immunoprecipitation with and immunoblotting using anti-HA; and
[0096] H: Anti-POMC after digitonin / Triton X-100-based cytosol / organelle fractionation with or without erastin (10 μM) treatment for 24 h SP Co-immunoprecipitation with and immunoblotting using anti-HA.
[0097] Figure 8 is a diagram confirming the inhibitory effect of POMC-induced Gpx4 degradation by cytoplasmic Hspa5:
[0098] A: Immunoblotting of apoptosis effectors Acsl4, Alox5, TfR1, POR, Nox1, Lpcat3, Slc40a1, Fsp1, HO1, and Nrf2;
[0099] B: Lipid ROS levels;
[0100] C: Cell viability;
[0101] D: Immunoblotting of Gpx4, CHOP, Nox2, and Nox4; and
[0102] E: CHX-trace analysis of Gpx4.
[0103] Figure 9 shows Marchf6, a POMC neuron-specific Marchf6-deficient mouse. POMC This study confirmed hyperphagia, decreased metabolic rate, and weight gain in mice:
[0104] A: Growth curve of male mice;
[0105] B: Growth curve of female mice;
[0106] C: Daily food intake of 20-week-old male mice;
[0107] D: Daily food intake of 20-week-old female mice;
[0108] E: Energy expenditure of 20-week-old male mice;
[0109] F: Energy expenditure of 20-week-old female mice; and
[0110] G to I: Quantitative data for immunohistochemically stained 4-HNE (G), Gpx4 (H), and Hspa5 (I) in POMC neurons from mice.
[0111] Fig. 10 is Marchf6 POMC Here is a diagram analyzing the weight gain of mice:
[0112] A: Body weight of 20-week-old male mice;
[0113] B: Body weight of 20-week-old female mice;
[0114] C: Fat mass of 20-week-old male mice;
[0115] D: Fat mass of 20-week-old female mice;
[0116] E: Lean body mass of 20-week-old male mice;
[0117] F: Lean body mass of 20-week-old male mice.
[0118] Fig. 11 is Marchf6 POMC Marchf6, the mouse's peer fl / fl Figure 1. IHC analysis of 4-HNE, Hspa5, and Gpx4 in POMC neurons of mice.
[0119] Figure 12. Marchf6 regulates ER stress, ferroptosis, and metabolic homeostasis in POMC neurons.
[0120] This is a schematic diagram showing the mechanism for controlling .
[0121] Hereinafter, the present invention will be described in detail with reference to the attached drawings and embodiments thereof. However, the following embodiments are provided as examples of the present invention. If a detailed description of a technology or configuration well known to those skilled in the art is judged to unnecessarily obscure the gist of the present invention, such detailed description may be omitted, and the present invention is not limited thereby. The present invention is capable of various modifications and applications within the scope of the following claims and equivalents interpreted therefrom.
[0122] Additionally, the terminology used in this specification is intended to appropriately express preferred embodiments of the present invention, and may vary depending on the intent of the user or operator, or the customs of the field to which the present invention pertains. Therefore, the definitions of these terms should be determined based on the contents throughout this specification. Throughout this specification, when a part is said to "include" a certain component, unless specifically stated otherwise, this does not mean that other components are excluded, but rather that other components may be included.
[0123] Unless otherwise defined, all technical terms used in this invention have the same meaning as commonly understood by those skilled in the art. While preferred methods and samples are described herein, similar or equivalent methods are also included within the scope of the present invention. The contents of all publications cited herein as references are incorporated herein by reference.
[0124] Throughout this specification, the conventional one-letter and three-letter codes for naturally occurring amino acids are used, as well as generally accepted three-letter codes for other amino acids, such as Aib (α-aminoisobutyric acid) and Sar (N-methylglycine). Furthermore, amino acids referred to herein by abbreviations are described according to the IUPAC-IUB nomenclature as follows:
[0125] Alanine: Ala, A; Arginine: Arg, R; Asparagine: Asn, N; Aspartic acid: Asp, D; Cysteine: Cys, C; Glutamic acid: Glu, E; Glutamine: Gln, Q; Glycine: Gly, G; Histidine: His, H; Isoleucine: IIe, I; Leucine: Leu, L; Lysine: Lys, K; Methionine: Met, M; Phenylalanine: Phe, F; Proline: Pro, P; Serine: Ser, S; Threonine: Thr, T; Tryptophan: Trp, W; Tyrosine: Tyr, Y; and Valine: Val, V.
[0126]
[0127] In one aspect, the present invention relates to an antigen peptide for producing an antibody specific for POMC (pro-opiomelanocortin), comprising the amino acid sequence of SEQ ID NO: 1.
[0128] In one embodiment, the antigenic peptide may be an isolated peptide, and may be an epitope or an epitope segment.
[0129] In one embodiment, the antigen peptide may be an antigen peptide for producing an antibody specific for POMC that includes a signal peptide (SP) sequence.
[0130] In one embodiment, the antigen peptide may further comprise a carrier protein, wherein the carrier protein may be Keyhole Limpet Hemocyanin (KLH), bovine serum albumin (BSA), or ovalbumin (OVA).
[0131] In one embodiment, the carrier protein can be linked to the antigen peptide via a linker, which can be a chemical linker.
[0132] In the present invention, a "peptide" is a polymer of amino acids. Usually, a form in which a small number of amino acids are linked is called a peptide, and a form in which many amino acids are linked is called a protein. The connection between amino acids in a peptide or protein structure is formed by an amide bond or a peptide bond. A peptide bond refers to a bond in which water (H2O) is lost between a carboxyl group (-COOH) and an amino group (-NH2) to form a -CO-NH-. The peptide of the present invention can be produced according to a chemical synthesis method known in the art, particularly solid-phase synthesis techniques (Merrifield, J. Amer. Chem. Soc. 85:2149-54 (1963); Stewart, et al., Solid Phase Peptide Synthesis, 2nd. ed., Pierce Chem. Co.: Rockford, 111 (1984)), and can also be produced by genetic engineering techniques.
[0133] Even if the present invention describes a 'peptide composed of a specific sequence number', if it has the same or corresponding activity as a peptide composed of the amino acid sequence of the sequence number, it does not exclude meaningless sequence additions before and after the amino acid sequence of the sequence number, mutations that may occur naturally, or silent mutations thereof, and it is clear that even if it has such sequence additions or mutations, it falls within the scope of the present invention.
[0134] In the present invention, modification of the peptide sequence may be one in which some amino acids are modified through any one of substitution, addition, deletion, and modification, or a combination of these methods. Such modifications include modifications using L- or D-amino acids, and / or non-natural amino acids; and / or modifications of the native sequence, such as modification of side chain functional groups, intramolecular covalent bonds such as ring formation between side chains, methylation, acylation, ubiquitination, phosphorylation, aminohexanoic acid oxidation, biotinylation, etc. The substituted or added amino acids may be the 20 amino acids commonly found in human proteins, as well as atypical or non-naturally occurring amino acids. Commercial sources of atypical amino acids include Sigma-Aldrich, ChemPep, and Genzyme pharmaceuticals. Peptides containing these amino acids and their typical peptide sequences can be synthesized and purchased from commercial peptide synthesis companies, such as American Peptide Company or Bachem in the United States, or Anygen in Korea.
[0135] In addition, the scope of the antigen peptide of the present invention includes functional equivalents of a peptide comprising the amino acid sequence of SEQ ID NO: 1, more preferably functional equivalents of a peptide comprising the amino acid sequence of SEQ ID NO: 1, and salts thereof.
[0136] The above functional equivalent refers to a peptide having at least 75%, preferably 90%, and more preferably 95% sequence homology (i.e., identity) with the peptide of SEQ ID NO: 1 as a result of addition, substitution, or deletion of amino acids, for example, 75, 76, 77, 78, 79, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100% sequence homology, and exhibiting substantially the same physiological activity as the peptide of SEQ ID NO: 1. In this specification, sequence homology and identity are defined as the percentage of amino acid residues in the candidate sequence relative to the amino acid sequence of SEQ ID NO: 1 after aligning the candidate sequence with the amino acid sequence of SEQ ID NO: 1 and introducing gaps. If necessary, conservative substitutions are not considered as part of the sequence identity to obtain the maximum percentage sequence identity. N-terminal, C-terminal, or internal extensions, deletions, or insertions of the amino acid sequence of SEQ ID NO: 1 are not construed as sequences that affect sequence identity or homology.
[0137] Additionally, the sequence identity can be determined by standard methods commonly used to compare similar portions of the amino acid sequences of two polypeptides. Computer programs such as BLAST or FASTA align two polypeptides so that each amino acid matches optimally (along the full length of one or both sequences or along predicted portions of one or both sequences). The programs provide default opening penalties and default gap penalties, and provide scoring matrices such as PAM250 (a standard scoring matrix) that can be used in conjunction with the computer program. For example, the percent identity can be calculated as follows: the total number of identical matches is multiplied by 100, and then divided by the sum of the length of the longer sequence within the matched span and the number of gaps introduced into the longer sequence to align the two sequences.
[0138] The scope of functional equivalents of the present invention includes derivatives and mimetics / peptidomimetics, and the term "derivative" collectively refers to a similar peptide in which a part of the chemical structure of the peptide is modified while maintaining the basic backbone of the peptide of SEQ ID NO: 1, and preferably, it may be a peptide in which one or more amino acids are substituted with other amino acids, one or more amino acids are added, one or more amino acids are deleted, or a peptide in which a compound that increases the half-life of the peptide (e.g., polyethylene glycol, etc.) is fused. In the present invention, the derivative may maintain, increase, or decrease the stability, storability, volatility, or solubility of the peptide according to the present invention.
[0139] In one aspect, the present invention relates to a composition for producing an antibody specific for POMC, comprising the antigenic peptide of the present invention.
[0140] In one embodiment, the composition may be a reagent composition for producing an antibody specific for POMC.
[0141] In one aspect, the present invention relates to a kit for producing an antibody specific for POMC, comprising the antigen peptide of the present invention.
[0142] The composition and kit for antibody production according to the present invention may additionally include a known component for maintaining and preserving the antigen peptide.
[0143] In one embodiment, the composition and kit for antibody production may further comprise a known agent for inducing and promoting an immune response in a host.
[0144] In one aspect, the present invention relates to a method for producing an antibody specific for POMC, comprising the steps of inducing an immune response by inoculating a host other than a human multiple times with an antigenic peptide of the present invention or a composition comprising the same; and obtaining serum from the blood of the host.
[0145] In one embodiment, the host may be a mammal other than a human, and the mammal other than a human may be a mouse, a rabbit, a rat, a guinea pig, a horse, a dog, a sheep, a goat, a cat, a chicken, a duck, a monkey or a primate, and is more preferably a rabbit, but is not limited thereto.
[0146] In one embodiment, the method may further comprise a step of purifying antibodies specific for POMC from the serum.
[0147] In one aspect, the present invention relates to an antibody or antigen-binding fragment specific for POMC that specifically binds to POMC prepared by the method of the present invention.
[0148] In one embodiment, an antibody or antigen-binding fragment specific for POMC of the present invention can specifically bind to POMC comprising an SP sequence.
[0149] In one embodiment, the antibody specific for POMC of the present invention may be a polyclonal antibody.
[0150] In one embodiment, the antibody or antigen-binding fragment specific for POMC of the present invention can bind to an epitope or epitope segment comprising the amino acid sequence of SEQ ID NO: 1.
[0151] In one embodiment, the POMC-specific antibody or antigen-binding fragment of the present invention can specifically bind to POMC present in the cytoplasm of POMC neurons.
[0152] In one embodiment, an antibody or antigen-binding fragment specific for POMC of the present invention can be used as a POMC neuron targeting composition in which POMC accumulates in the cytoplasm.
[0153] In one embodiment, the antibody or antigen-binding fragment specific for POMC may also comprise a tag, a labeled moiety, or additional amino acid sequences designed for the specific purpose of increasing the half-life or stability of the protein.
[0154] In one embodiment, the tag can be a His tag, a Myc (c-myc) tag, a FLAG tag, an HA tag, or a T7 tag.
[0155] In one embodiment, the antibody or antigen-binding fragment specific for POMC of the present invention may further comprise a detectable label, wherein the label may be a fluorescent label, a chemiluminescent label, an enzymatic label, and a radionuclide label, and the fluorescent label may be green fluorescent protein (GFP), enhanced green fluorescent protein (EGFP), yellow fluorescent protein (YFP), red fluorescent protein (RFP), orange fluorescent protein (OFP), cyan fluorescent protein (CFP), blue fluorescent protein (BFP), far-red fluorescent protein, or a tetracysteine motif.
[0156] In one embodiment, an antibody or antigen-binding fragment specific for POMC may be further conjugated to an RNA, DNA, antibody, effector, drug, prodrug, toxin, peptide or delivery molecule (see Shoari et al., Pharmaceutics 13:1391, pp. 1-32 (2021)).
[0157] In one embodiment, the drug may be a gene, plasmid DNA, antisense oligonucleotide, siRNA, peptide, ribozyme, viral particle, immunomodulator, protein, contrast agent, or the like.
[0158] The complex of the POMC-specific antibody or antigen-binding fragment of the present invention with a drug can be prepared as a pharmaceutical composition in the form of an oral dosage form or a parenteral dosage form depending on the route of administration by a conventional method known in the art, including a pharmaceutically acceptable carrier. Here, "pharmaceutically acceptable carrier" refers to a carrier or diluent that does not stimulate a living organism and does not inhibit the biological activity and properties of the administered compound. In the composition formulated as a liquid solution, acceptable pharmaceutical carriers are sterile and biocompatible, and include saline solution, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, ethanol, and a mixture of one or more of these components. If necessary, other conventional additives such as antioxidants, buffers, and bacteriostatic agents can be added.
[0159] In the present invention, the term "antibody" refers to a functional component of serum and is often referred to as a collection of molecules (antibodies or immunoglobulins) or a single molecule (antibody molecule or immunoglobulin molecule). Antibody molecules can bind to or react with specific antigenic determinants (antigens or antigenic epitopes), which in turn induce immunological effector mechanisms.
[0160] Individual antibody molecules are generally considered monospecific, and their composition may be monoclonal (i.e., composed of identical antibody molecules) or polyclonal (i.e., composed of different antibody molecules that react with the same or different epitopes on the same antigen or on separate antigens). Each antibody molecule has a unique structure that enables it to specifically bind to its corresponding antigen, and all natural antibody molecules have the same overall basic structure of two identical light chains and two identical heavy chains. Antibodies are also known collectively as immunoglobulins. The term antibody or antibodies as used herein is used in the broadest sense and includes intact antibodies, chimeric antibodies, humanized antibodies, fully human, and single-chain antibodies, as well as binding fragments of antibodies, such as Fab, Fv fragments, or scFv fragments, and multimeric forms, such as dimeric IgA molecules or pentavalent IgM.
[0161] In the present invention, the terms “specifically bind” or “specifically recognize” have the same meaning as commonly known to those skilled in the art, and mean that an antigen and an antibody specifically interact to cause an immunological reaction.
[0162] In the present invention, the term "epitope" is generally used to describe a portion of a larger molecule or a part of a larger molecule (e.g., an antigen or antigenic site) that has antigenic or immunogenic activity in an animal, preferably a mammal, and most preferably a human. An epitope having immunogenic activity is a portion of a larger molecule that elicits an antibody response in an animal. An epitope having antigenic activity is a portion of a larger molecule to which an antibody immunospecifically binds, as determined by any method well known in the art, for example, an immunoassay as described herein. An antigenic epitope need not necessarily be immunogenic. An antigen is a substance to which an antibody or antibody fragment immunospecifically binds, such as a toxin, virus, bacteria, protein, or DNA. An antigen or antigenic site, unless it is very small, often has more than one epitope, and can often stimulate an immune response. Antibodies that bind to different epitopes on the same antigen can have varying effects on the activity of the antigen they bind, depending on the location of the epitope. An antibody that binds to an epitope at the active site of the antigen completely blocks the antigen's function, while another antibody that binds to a different epitope has little or no effect on the antigen's activity.
[0163] As used herein, the term "polyclonal (polyclonal) antibody" refers to a composition of different (diverse) antibody molecules capable of binding to or reacting with several different specific antigenic determinants / epitopes on the same or different antigens, wherein each individual antibody in the composition can react with a specific epitope. Typically, the variability of a polyclonal antibody lies in the so-called variable regions of the polyclonal antibody, particularly the CDR1, CDR2, and CDR3 regions. In the present invention, the polyclonal antibody may be produced in a single pot, or may be a mixture of different polyclonal antibodies. A mixture of monoclonal antibodies is not considered a polyclonal antibody per se, as it is produced in individual batches and need not necessarily come from the same organism or cell line, which would result in differences in post-translational modifications, for example. However, a mixture of monoclonal antibodies would be considered equivalent to a polyclonal antibody if it provided the same antigen / epitope coverage as the polyclonal antibodies of the present invention.
[0164] In one aspect, the present invention relates to a pharmaceutical composition for preventing or treating a POMC accumulation-related disease, comprising an antibody or antigen-binding fragment specific for POMC of the present invention as an active ingredient.
[0165] In one embodiment, the POMC accumulation-related disease may be a disease in which POMC accumulates in the cytoplasm of POMC neurons and may be a metabolic disease.
[0166] In one embodiment, the metabolic disease may be any one selected from the group consisting of obesity, bulimia, diabetes, arteriosclerosis, hypertension, hyperlipidemia, fatty liver, metabolic liver disease, and cardiovascular disease, and may be obesity, and more preferably, obesity caused by a hypothalamic disorder.
[0167] In one embodiment, obesity caused by a hypothalamic disorder may be obesity caused by ER stress or ferroptosis caused by POMC protein accumulating in the cytoplasm of POMC neurons of the hypothalamus, and the obesity may have symptoms of binge eating, increased appetite, and decreased energy metabolism.
[0168] In one aspect, the present invention relates to a pharmaceutical composition for preventing or treating a disease related to Marchf6 (membrane associated ring-CH-type finger 6) dysfunction, comprising an antibody or antigen-binding fragment specific for POMC of the present invention as an active ingredient.
[0169] In one implementation, the function of Marchf6 may be to degrade SP-containing POMC in the cytoplasm of POMC neurons, thereby transporting POMC to the ER by inhibiting lipid peroxidation.
[0170] In one embodiment, the disease may be a disease in which the function of Marchf6, which degrades the SP sequence of cytoplasmic POMC, is reduced, and may be a metabolic disease, most preferably obesity.
[0171] In the present invention, the term "prevention" refers to any action that inhibits or delays the occurrence, spread, and recurrence of a disease by administering the pharmaceutical composition according to the present invention, and "treatment" refers to any action that improves or beneficially changes the symptoms of a disease by administering the composition of the present invention. Those of ordinary skill in the art to which the present invention pertains will be able to refer to materials presented by the Korean Medical Association and other sources to understand the exact criteria for diseases for which the composition of the present invention is effective, and to determine the degree of improvement, enhancement, and treatment.
[0172] The term "therapeutically effective amount" used in combination with the active ingredient in the present invention means an amount effective in preventing or treating a target disease, and the therapeutically effective amount of the composition of the present invention may vary depending on various factors, such as the administration method, target site, and patient condition. Therefore, the dosage for use in humans should be determined as an appropriate amount by taking both safety and efficacy into consideration. It is also possible to estimate the amount used in humans from the effective amount determined through animal testing. Such considerations in determining the effective amount are described, for example, in Hardman and Limbird, eds., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th ed.(2001), Pergamon Press; and E.W. Martin ed., Remington's Pharmaceutical Sciences, 18th ed.(1990), Mack Publishing Co.
[0173] The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount. The term "pharmaceutically effective amount" as used herein means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment and not causing side effects. The effective dosage level may be determined based on factors including the patient's health condition, the type of the disease, the cause of the disease, the severity, the activity of the drug, the sensitivity to the drug, the method of administration, the time of administration, the route of administration and the excretion rate, the duration of treatment, the drugs used in combination or simultaneously, and other factors well known in the medical field. The composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered singly or in multiple doses. Taking all of the above factors into consideration, it is important to administer an amount that can achieve the maximum effect with the minimum amount without side effects, and this can be easily determined by those skilled in the art.
[0174] The pharmaceutical composition of the present invention may include a carrier, diluent, excipient, or a combination of two or more thereof commonly used in biological preparations. The term "pharmaceutically acceptable" as used herein means that the composition exhibits a characteristic of not being toxic to cells or humans exposed to the composition. The carrier is not particularly limited as long as it is suitable for delivering the composition in vivo, and for example, compounds described in Merck Index, 13th ed., Merck & Co. Inc., saline solution, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol, and one or more of these components may be mixed and used, and other common additives such as antioxidants, buffers, and bacteriostatic agents may be added as necessary. In addition, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to formulate the composition into a main use form such as an aqueous solution, suspension, or emulsion, pills, capsules, granules, or tablets. Furthermore, it can be preferably formulated according to each disease or ingredient using an appropriate method in the field or the method disclosed in Remington's Pharmaceutical Science (Mack Publishing Company, Easton PA, 18th, 1990).
[0175] In one embodiment, the pharmaceutical composition may be in one or more dosage forms selected from the group consisting of oral dosage forms, topical preparations, suppositories, sterile injectable solutions and sprays, with oral or injectable dosage forms being more preferred.
[0176] The term "administration" used in the present invention means providing a predetermined substance to an individual or patient by any appropriate method, and may be administered parenterally (for example, intravenously, subcutaneously, intraperitoneally, or locally in the form of an injection) or orally depending on the intended method, and the dosage range varies depending on the patient's weight, age, sex, health condition, diet, administration time, administration method, excretion rate, and severity of the disease. Liquid preparations for oral administration of the composition of the present invention include suspensions, oral solutions, emulsions, syrups, etc., and may include various excipients such as wetting agents, sweeteners, fragrances, preservatives, etc. in addition to commonly used simple diluents such as water and liquid paraffin. Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories, etc. The pharmaceutical composition of the present invention may be administered by any device that allows the active substance to move to target cells. Preferred administration methods and formulations include intravenous injection, subcutaneous injection, intradermal injection, intramuscular injection, and drip injection. Injections can be manufactured using aqueous solvents such as saline solution and Ringer's solution, non-aqueous solvents such as vegetable oil, higher fatty acid ester (e.g., ethyl oleate, etc.), alcohols (e.g., ethanol, benzyl alcohol, propylene glycol, glycerin, etc.), and pharmaceutical carriers such as stabilizers to prevent deterioration (e.g., ascorbic acid, sodium bisulfite, sodium pyrosulfite, BHA, tocopherol, EDTA, etc.), emulsifiers, buffers to adjust pH, and preservatives to inhibit microbial growth (e.g., phenylmercuric nitrate, thimerosal, benzalkonium chloride, phenol, cresol, benzyl alcohol, etc.).
[0177] The term "subject" used in the present invention means a subject that has developed or is developing the disease.
[0178] Monkeys, cows, horses, sheep, pigs, chickens, turkeys, quails, cats, including humans who can do it
[0179] This refers to all animals, including dogs, mice, rats, rabbits, or guinea pigs, and the above diseases can be effectively prevented or treated by administering the pharmaceutical composition of the present invention to the subject. The pharmaceutical composition of the present invention can be administered in conjunction with existing therapeutic agents.
[0180] The pharmaceutical composition of the present invention may further include a pharmaceutically acceptable additive. At this time, the pharmaceutically acceptable additive may include starch, gelatinized starch, microcrystalline cellulose, lactose, povidone, colloidal silicon dioxide, calcium hydrogen phosphate, lactose, mannitol, maltose, gum arabic, pregelatinized starch, corn starch, powdered cellulose, hydroxypropyl cellulose, Opadry, sodium starch glycolate, carnauba wax, synthetic aluminum silicate, stearic acid, magnesium stearate, aluminum stearate, calcium stearate, sucrose, dextrose, sorbitol, and talc. The pharmaceutically acceptable additive according to the present invention is preferably included in the composition in an amount of 0.1 to 90 parts by weight, but is not limited thereto.
[0181] The pharmaceutical composition of the present invention can be used as a single therapy, but can also be used in combination with other conventional biological therapy or chemotherapy, and when such combination therapy is performed, the disease can be treated more effectively.
[0182] In one aspect, the present invention relates to a composition for diagnosing a POMC accumulation-related disease, comprising an antibody or antigen-binding fragment specific for POMC of the present invention as an active ingredient.
[0183] In one embodiment, a diagnostic composition comprising an antibody of the present invention or a fragment having immunological activity thereof can be used to detect the accumulation of POMC or measure the amount (level) thereof in a biological sample isolated from a subject.
[0184] The term “detection” or “measurement” used in the present invention means quantifying the presence or absence of a detected or measured object or its concentration.
[0185] In one aspect, the present invention relates to a composition for diagnosing a disease associated with Marchf6 dysfunction, comprising an antibody or antigen-binding fragment specific for POMC of the present invention as an active ingredient.
[0186] In one aspect, the present invention relates to a method for providing information for diagnosing a metabolic disease, which comprises detecting POMC accumulated in the cytoplasm of POMC neurons in a biological sample isolated from a subject using an antibody or antigen-binding fragment specific for POMC of the present invention.
[0187] In one embodiment, the metabolic disease may be any one selected from the group consisting of obesity, bulimia, diabetes, arteriosclerosis, hypertension, hyperlipidemia, fatty liver, metabolic liver disease, and cardiovascular disease, and obesity is more preferred.
[0188] In one aspect, the present invention relates to a method for detecting POMC accumulated in the cytoplasm of POMC neurons, comprising the step of treating a sample with an antibody or antigen-binding fragment of the present invention to induce an antigen-antibody reaction.
[0189] The term "sample" as used herein refers to a biological sample obtained from a subject or patient. The source of the biological sample may be a fresh, frozen, and / or preserved organ or tissue sample, or solid tissue from a biopsy or aspirate; blood or any blood component; or cells from any point in the subject's pregnancy or development.
[0190] In one aspect, the present invention relates to a kit for diagnosing metabolic diseases comprising an antibody or antigen-binding fragment specific for the POMC of the present invention.
[0191] In one embodiment, the kit may further include tools and / or reagents for collecting a biological sample from a subject or patient, as well as tools and / or reagents for preparing POMC from the sample.
[0192]
[0193] In one aspect, the present invention relates to a pharmaceutical composition for preventing or treating a metabolic disease, comprising a Marchf6 protein or a fragment thereof, or an activator or expression promoter of Marchf6 as an active ingredient.
[0194] In one embodiment, the fragment of Marchf6 may comprise a C4 region comprising amino acids 443 to 480 of the Marchf6 protein.
[0195] In one embodiment, the fragment of Marchf6 may include C9, the 9th amino acid, and P460, the 460th amino acid in the amino acid sequence.
[0196] In one embodiment, the Marchf6 protein may be a variant or analog thereof, wherein the variant or analog may be a functional equivalent that retains the activity of degrading POMC.
[0197] In one embodiment, the Marchf6 protein can inhibit the degradation of Gpx4.
[0198] In one embodiment, the Marchf6 protein can prevent lipid peroxidation.
[0199] In one embodiment, the Marchf6 protein or fragment thereof may further comprise additional amino acid sequences designed for the specific purpose of increasing targeting sequences, tags, labeled residues, half-life or stability of the protein, and may further comprise a conjugated peptide / protein capable of binding to POMC neurons of the hypothalamus.
[0200] In one embodiment, the Marchf6 protein or fragment thereof can be linked to a coupling partner such as an effector, drug, prodrug, toxin, peptide, delivery molecule, or the like.
[0201] In one embodiment, the activator or expression promoter of Marchf6 may be a compound, peptide, aptamer, primer, probe or antibody that specifically binds to the Marchf6 protein or a gene encoding it.
[0202] In one embodiment, the expression promoter may be a recombinant vector comprising a nucleic acid encoding Marchf6 or a fragment thereof.
[0203] In one embodiment, the Marchf6 protein or fragment thereof, or the activated or increased expression of Marchf6 by an activator or expression promoter of Marchf6, can remove SP-uncleaved POMC that fails to move from the cytoplasm to the ER.
[0204] In one embodiment, Marchf6 degrades SP-containing POMC in the cytoplasm of POMC neurons, and Marchf6 regulates POMC translocation to the ER by inhibiting lipid peroxidation.
[0205] In one embodiment, the recombinant vector may further comprise a hypothalamic POMC neuron targeting ligand.
[0206] In one embodiment, the recombinant vector may further comprise a transcriptional regulator, a translational regulator or a marker capable of determining gene expression.
[0207] In one embodiment, the marker may be an antibiotic resistance gene, a selectable marker gene, a β glucuronidase encoding gene, a chloramphenicol acetyltransferase, a luciferase, or a fluorescent protein encoding gene.
[0208] In one embodiment, the selection marker gene may be selected from the group consisting of neomycin phosphotransferase, hygromycin phosphotransferase, puromycin, histidinol dehydrogenase, guanine phosphotransferase, and zeocin, and is more preferably a hygromycin phosphotransferase (htpII) gene.
[0209] In one embodiment, the fluorescent protein may be green fluorescent protein (GFP), enhanced green fluorescent protein (EGFP), yellow fluorescent protein (YFP), red fluorescent protein (RFP), orange fluorescent protein (OFP), cyan fluorescent protein (CFP), blue fluorescent protein (BFP), far-red fluorescent protein, or a tetracysteine motif.
[0210] In one embodiment, the recombinant vector may comprise a tag sequence, wherein the tag may be a His tag, a Myc (c-myc) tag, a FLAG tag, an HA tag, or a T7 tag.
[0211] In one embodiment, the composition may further comprise an activator or expression promoter of Bag6, Derl1 or VCP.
[0212] In one embodiment, the metabolic disease may be any one selected from the group consisting of obesity, bulimia, diabetes, arteriosclerosis, hypertension, hyperlipidemia, fatty liver, metabolic liver disease, and cardiovascular disease, and may be obesity, and more preferably obesity caused by a hypothalamic disorder.
[0213] In one embodiment, the metabolic disorder may be obesity caused by ER stress or ferroptosis resulting from POMC protein accumulating in the cytoplasm of POMC neurons in the hypothalamus, which may have symptoms of binge eating, increased appetite, and decreased energy metabolism.
[0214] As used herein, the term "variant" refers to a corresponding amino acid sequence that contains at least one amino acid difference (substitution, insertion, or deletion) compared to a reference sequence. In certain embodiments, a "variant" has high amino acid sequence homology and / or conservative amino acid substitutions, deletions, and / or insertions compared to a reference sequence.
[0215] The protein variant according to the present invention is interpreted to mean a variant in which an amino acid residue is conservatively substituted at a specific amino acid residue position.
[0216] As used herein, "conservative substitution" refers to a modification of a variant that involves replacing one or more amino acids with amino acids having similar biochemical properties that do not result in a loss of the biological or biochemical function of the Marchf6 protein or fragment thereof. A "conservative amino acid substitution" is a substitution that replaces an amino acid residue with an amino acid residue having a similar side chain. Classes of amino acid residues having similar side chains are well known and defined in the art. These classes include amino acids with basic side chains (e.g., lysine, arginine, histidine), amino acids with acidic side chains (e.g., aspartic acid, glutamic acid), amino acids with uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), amino acids with non-polar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), amino acids with beta-branched side chains (e.g., threonine, valine, isoleucine), and amino acids with aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine).
[0217] As used herein, the term "analog" may include protein analogs in which the side chains or alpha-amino acid backbones of amino acids are substituted with one or more other functional groups. Examples of protein analogs with side chain or backbone modifications include, but are not limited to, hydroxyproline, in which the pyrrolidine ring is substituted with a hydroxy group, or N-methyl glycine "peptoids." The types of protein / peptide analogs are well known in the art.
[0218] The term "nucleic acid" as used in the present invention refers to deoxyribonucleotides or ribonucleotides existing in single-stranded or double-stranded form, and includes natural nucleic acid analogs unless specifically stated otherwise (Scheit, Nucleotide Analogs, John Wiley, New York (1980); Uhlman and Peyman, Chemical Reviews, 90:543584 (1990)).
[0219] In this specification, the term "expression promoter" refers to a substance that directly or indirectly acts on Marchf6 to improve, induce, stimulate, or increase the expression of Marchf6, and the type of the substance is not limited. The mechanism by which the substance promotes the expression of Marchf6 is not particularly limited, and for example, it may act as a mechanism to increase gene expression such as transcription or translation, or to convert an inactive form to an active form.
[0220] In this specification, "recombination vector" refers to a general term for a vector produced to be able to express Marchf6, and preferably includes a liposome, a plasmid vector, a cosmid vector, a bacteriophage vector, a viral vector, etc., and is not limited thereto as long as it is a vector capable of expressing Marchf6 in vivo. Examples of the viral vector include adenovirus, adeno-associated virus, retrovirus, lentivirus, herpes simplex virus, alpha virus, etc.
[0221] The pharmaceutical composition of the present invention may additionally include a known metabolic disease treatment agent in addition to the Marchf6 protein or a fragment thereof, or an activator or expression promoter of Marchf6 as an active ingredient, and may be used in combination with other known treatments for the treatment of these diseases.
[0222] In the present invention, the term "prevention" means any action that inhibits or delays the occurrence, spread, and recurrence of a metabolic disease by administering a pharmaceutical composition according to the present invention, and "treatment" means any action that improves or beneficially changes the symptoms of a metabolic disease by administering the composition of the present invention. Those of ordinary skill in the art to which the present invention pertains will be able to refer to materials presented by the Korean Medical Association, etc. to know the exact criteria for diseases to which the composition of the present invention is effective, and to determine the degree of improvement, enhancement, and treatment.
[0223] The term “therapeutically effective amount” used in combination with the active ingredient in the present invention refers to
[0224] It means an amount effective for preventing or treating a target disease, and the therapeutically effective amount of the composition of the present invention may vary depending on various factors, such as the administration method, target site, and patient's condition. Therefore, the dosage for use in humans should be determined as an appropriate amount by considering both safety and efficacy. It is also possible to estimate the amount used in humans from the effective amount determined through animal testing. Such considerations when determining the effective amount are described in, for example, Hardman and Limbird, eds., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th ed.(2001), Pergamon Press; and E.W. Martin ed., Remington's Pharmaceutical Sciences, 18th ed.(1990), Mack Publishing Co.
[0225] The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount. The term "pharmaceutically effective amount" as used herein means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment and not causing side effects. The effective dosage level may be determined based on factors including the patient's health condition, type of metabolic disease, cause of metabolic disease, severity, activity of the drug, sensitivity to the drug, method of administration, time of administration, route of administration and excretion rate, duration of treatment, combination or concurrent use of drugs, and other factors well known in the medical field. The composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered singly or in multiple doses. Taking all of the above factors into consideration, it is important to administer an amount that can achieve the maximum effect with the minimum amount without side effects, and this can be easily determined by those skilled in the art.
[0226] The pharmaceutical composition of the present invention may include a carrier, diluent, excipient, or a combination of two or more thereof commonly used in biological preparations. The term "pharmaceutically acceptable" as used herein means that the composition exhibits a characteristic of not being toxic to cells or humans exposed to the composition. The carrier is not particularly limited as long as it is suitable for delivering the composition in vivo, and for example, compounds described in Merck Index, 13th ed., Merck & Co. Inc., saline solution, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol, and one or more of these components may be mixed and used, and other common additives such as antioxidants, buffers, and bacteriostatic agents may be added as necessary. In addition, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to formulate the composition into a main use form such as an aqueous solution, suspension, or emulsion, pills, capsules, granules, or tablets. Furthermore, it can be preferably formulated according to each disease or ingredient using an appropriate method in the field or the method disclosed in Remington's Pharmaceutical Science (Mack Publishing Company, Easton PA, 18th, 1990).
[0227] In one embodiment, the pharmaceutical composition may be in one or more dosage forms selected from the group consisting of oral dosage forms, topical preparations, suppositories, sterile injectable solutions and sprays, with oral or injectable dosage forms being more preferred.
[0228] The term "administration" used in the present invention means providing a predetermined substance to an individual or patient by any appropriate method, and may be administered parenterally (for example, intravenously, subcutaneously, intraperitoneally, or locally in the form of an injection) or orally depending on the intended method, and the dosage range varies depending on the patient's weight, age, sex, health condition, diet, administration time, administration method, excretion rate, and severity of the disease. Liquid preparations for oral administration of the composition of the present invention include suspensions, oral solutions, emulsions, syrups, etc., and may include various excipients such as wetting agents, sweeteners, fragrances, preservatives, etc. in addition to commonly used simple diluents such as water and liquid paraffin. Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories, etc. The pharmaceutical composition of the present invention may be administered by any device that allows the active substance to move to target cells. Preferred administration methods and formulations include intravenous injection, subcutaneous injection, intradermal injection, intramuscular injection, and drip injection. Injections can be manufactured using aqueous solvents such as saline solution and Ringer's solution, non-aqueous solvents such as vegetable oil, higher fatty acid ester (e.g., ethyl oleate, etc.), alcohols (e.g., ethanol, benzyl alcohol, propylene glycol, glycerin, etc.), and pharmaceutical carriers such as stabilizers to prevent deterioration (e.g., ascorbic acid, sodium bisulfite, sodium pyrosulfite, BHA, tocopherol, EDTA, etc.), emulsifiers, buffers to adjust pH, and preservatives to inhibit microbial growth (e.g., phenylmercuric nitrate, thimerosal, benzalkonium chloride, phenol, cresol, benzyl alcohol, etc.).
[0229] The term "subject" used in the present invention means any animal, including humans, monkeys, cows, horses, sheep, pigs, chickens, turkeys, quails, cats, dogs, mice, rats, rabbits, or guinea pigs, that has developed or may develop the metabolic disease, and the above diseases can be effectively prevented or treated by administering the pharmaceutical composition of the present invention to the subject. The pharmaceutical composition of the present invention can be administered in combination with existing therapeutic agents.
[0230] The pharmaceutical composition of the present invention may further include a pharmaceutically acceptable additive. At this time, the pharmaceutically acceptable additive may include starch, gelatinized starch, microcrystalline cellulose, lactose, povidone, colloidal silicon dioxide, calcium hydrogen phosphate, lactose, mannitol, maltose, gum arabic, pregelatinized starch, corn starch, powdered cellulose, hydroxypropyl cellulose, Opadry, sodium starch glycolate, carnauba wax, synthetic aluminum silicate, stearic acid, magnesium stearate, aluminum stearate, calcium stearate, sucrose, dextrose, sorbitol, and talc. The pharmaceutically acceptable additive according to the present invention is preferably included in the composition in an amount of 0.1 to 90 parts by weight, but is not limited thereto.
[0231] The pharmaceutical composition of the present invention can be used as a single therapy, but can also be used in combination with other conventional biological therapy or chemotherapy, and when such combination therapy is performed, metabolic diseases can be treated more effectively.
[0232] The present invention provides a method for preventing or treating a disease or metabolic disease related to Marchf6 (membrane associated ring-CH-type finger 6) dysfunction, comprising a step of administering the pharmaceutical composition to a subject in a pharmaceutically effective manner.
[0233] In one aspect, the present invention relates to a composition for promoting POMC (pro-opiomelanocortin) degradation, comprising a Marchf6 protein or a fragment thereof, or an activator or expression promoter of Marchf6.
[0234] In one embodiment, the composition can promote the degradation of POMC in the cytoplasm of POMC neurons.
[0235] In one embodiment, the fragment of Marchf6 may comprise a C4 region comprising amino acids 443 to 480 of the Marchf6 protein.
[0236] In one embodiment, the fragment of Marchf6 may include C9, the 9th amino acid, and P460, the 460th amino acid in the amino acid sequence.
[0237] In one embodiment, the expression promoter may be a recombinant vector comprising a nucleic acid encoding Marchf6 or a fragment thereof.
[0238] In one embodiment, the P460 region of Marchf6 can recognize a region containing the signal peptide (SP) of POMC as a degron, thereby inducing degradation of POMC.
[0239] In one aspect, the present invention relates to a composition for promoting translocation to the ER, comprising a Marchf6 protein or a fragment thereof, or an activator or expression promoter of Marchf6.
[0240] In one aspect, the present invention relates to a composition for inhibiting ER stress or ferroptosis in POMC neurons, comprising a Marchf6 protein or a fragment thereof, or an activator or expression promoter of Marchf6.
[0241] In one embodiment, the composition can inhibit increased ER stress or ferroptosis induced by excess POMC or cytoplasmic residual POMC.
[0242] In one embodiment, the P460 region of Marchf6 in the cytoplasm of POMC neurons recognizes the region containing the signal peptide (SP) of POMC as a degron, thereby degrading POMC and transporting POMC to the ER, thereby preventing / inhibiting ER stress and ferroptosis.
[0243] In one aspect, the present invention relates to a food composition for preventing or improving metabolic diseases, comprising a Marchf6 protein or a fragment thereof, or an activator or expression promoter of Marchf6 as an active ingredient.
[0244] When the composition of the present invention is used as a food composition, the Marchf6 protein or a fragment thereof, or an activator or expression promoter of Marchf6, may be added as is or used together with other foods or food ingredients, and may be used appropriately according to a conventional method. The composition may include a food-related acceptable food additive in addition to the active ingredient, and the mixing amount of the active ingredient may be appropriately determined depending on the purpose of use (prevention, health, or therapeutic treatment).
[0245] The term "food supplement additive" used in the present invention means a component that can be added to food as an auxiliary, and can be appropriately selected and used by a person skilled in the art as added in the manufacture of health functional foods of each formulation. Examples of food supplement additives include various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic flavoring agents and natural flavoring agents, coloring agents and fillers, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc., but the types of food supplement additives of the present invention are not limited by the above examples.
[0246] The food composition of the present invention may include a health functional food. The term "health functional food" as used in the present invention refers to a food manufactured and processed in the form of tablets, capsules, powders, granules, liquids, pills, etc. using raw materials or ingredients having functionality useful to the human body. Here, "functionality" means obtaining a useful effect for health purposes, such as regulating nutrients for the structure and function of the human body or physiological functions. The health functional food of the present invention can be manufactured by a method commonly used in the art, and during the manufacturing process, raw materials and ingredients commonly added in the art can be added. In addition, the formulation of the health functional food can also be manufactured without limitation as long as it is a formulation recognized as a health functional food. The food composition of the present invention can be manufactured in various forms, and the health functional food of the present invention can be ingested as a supplement to enhance the effect of a metabolic disease treatment agent.
[0247] In addition, there is no limitation on the type of health food in which the composition of the present invention can be used. In addition, a composition comprising the Marchf6 protein or a fragment thereof, or an activator or expression promoter of Marchf6 as an active ingredient of the present invention can be prepared by mixing other appropriate auxiliary ingredients that can be included in health functional foods and known additives according to the selection of a person skilled in the art. Examples of foods to which the composition can be added include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, ice cream, various soups, beverages, tea, drinks, alcoholic beverages, and vitamin complexes, and the like can be prepared by adding the extract according to the present invention to juice, tea, jelly, and juice made with the extract as a main ingredient.
[0248] In one aspect, the present invention relates to a method for screening for an obesity treatment agent, comprising the steps of treating cells isolated from an individual with a candidate substance; determining the level of Marchf6 expression or activation in the cells treated with the candidate substance; and comparing the level of Marchf6 expression or activation with a control group.
[0249] In one embodiment, the cell may be a POMC neuron.
[0250]
[0251] The present invention is described in more detail through the following examples. However, the following examples are intended only to concretize the content of the present invention and are not intended to limit the present invention.
[0252]
[0253] Example 1. Search for proteins that interact with Marchf6.
[0254] To investigate proteins that bind to Marchf6 (membrane associated ring-CH-type finger 6), yeast two-hybrid (Y2H) analysis was performed using eight cytoplasmically facing regions (C1 to C8) of Marchf6. Specifically, S. cerevisiaeAH109 (CHY726) cells were transformed with a human cDNA library (638820, Clontech) as bait (Fig. 1). Fourteen library plasmids were recovered from ~100 positive clones among ~1 × 106 transformants and analyzed by DNA sequencing to select nine plasmids carrying specific human genes (Fig. 1B). In addition, to further confirm the interaction of molecules found to bind to each region of Marchf6 with full-length Marchf6, pCH836 (Marchf6) as bait and pCH4203 (POMC), pCH7140 (Bnip3), pCH7141 (Gps1), pCH7142 (SNAPIN), pCH7143 (Yif1a), pCH7144 (Hspa5), pCH7145 (Hax1), pCH7146 (Fhl2), and pCH7147 (Mcfd2) as prey were co-transformed into CHY712S. cerevisiae cells and split-Ub analysis was performed. The resulting transformants were A 600= 1, and the transformed cells were serially diluted 5-fold and spotted onto SC(-Leu / -Trp) or SC(-Leu / -Trp / -His) plates, followed by incubation at 30°C for 3 days. Among these transformants, only yeast cells harboring pCH836 (Marchf6) and pCH4203 (POMC) survived on SC plates (-Leu / -Trp / -His), confirming that POMC binds to full-length Marchf6 (Fig. 1C), indicating an interaction between Marchf6 and POMC.
[0255]
[0256] Example 2. Exploration of the interaction site between Marchf6 and POMC.
[0257] 2-1. Y2H analysis and split-Ub analysis
[0258] To determine which residues in the C4 region of Marchf6 that interact with POMC in Example 1 are important for interacting with POMC, pCH4540 (C4) and its amino acid substitution mutants of conserved regions, pCH4158 (C4) R443A ), pCH4159 (C4 R447A ), pCH4160 (C4 L451A ), pCH4161 (C4 D459A ), pCH4162 (C4 P460A ) and pCH4163(C4 R479A ) were co-transformed into CHY726 together with pCH4132 (POMC), respectively. Transformants containing the generated bait and prey plasmids were spotted on SC plates and cultured at 30°C for 3 days.
[0259] As a result, among the C4 domains of Marchf6 that specifically bind to POMC, only the P460A (Pro460-to-Ala) mutation was found to have lost binding affinity, unlike the mutations R443A (Arg443-to-Ala), R447A (Arg447-to-Ala), L451A (Leu451-to-Ala), D459A (Asp459-to-Ala), and R479A (Arg479-to-Ala) (Fig. 2A to C).
[0260]
[0261] 2-2. Chemical Cross-linking-Based Mutual Co-Immunoprecipitation Assay
[0262] For chemical crosslinking-based reciprocal co-immunoprecipitation assay, HEK293T cells were cultured at ~70% confluency in 10-cm dish plates and transfected with pCH60 (empty vector) or pCH4129 (exogenous C-terminally hemagglutinin (ha)-tagged POMC: POMC ha ) 2 μg and pCH879 (wild-type C-terminal triple flag-tagged Marchf6: Marchf6 3f ) or pCH4170 (Marchf6 3f P460A) were co-transfected and incubated for 48 h. Cells were washed with PBS, treated with 1 mM DSP [dithiobis(succinimidyl propionate)] (Thermo Fisher, 22585), and cross-linked cells were lysed and immunoprecipitated. Beads were washed three times with IP-wash buffer (20 mM Tris-HCl, 137 mM NaCl, 0.1% NP-40, 2 mM EDTA, 10% glycerol), and bound proteins were eluted with 2XSDS sample buffer. For immunoprecipitation with FLAG-agarose (Sigma-Aldrich, A2220), 3XFLAG peptide (Protein Ark, GEN-3XFLAG-5) was used. Afterwards, the eluate was denatured and heated at 37°C for 20 minutes, and SDS-PAGE and immunoblotting were performed using the corresponding antibody.
[0263] As a result, POMC in the battlefield specifically binds to Marchf6, but Marchf6 P460A It was confirmed that POMC binds to P460 of the C4 region of Marchf6, although it did not appear to bind to P460 (Fig. 2D and E).
[0264]
[0265] Example 3. Confirmation of POMC degradation through interaction between Marchf6 and POMC.
[0266] 3-1. Analysis of the POMC degradation mechanism of Marchf6
[0267] To confirm whether POMC is specifically recognized by Marchf6 Ub ligase and undergoes proteasomal degradation, cycloheximide (CHX)-tracking analysis of protein degradation and ubiquitylation analysis were performed. Specifically, for CHX-tracking analysis, Marchf6-KO N43 / 5 cells, constructed using the CRISPR / Cas9 system with sgRNA targeting exon 6 of the Marchf6 locus, were seeded at a density of 1 × 105 cells, cultured for 24 h, and treated with CHX at a final concentration of 50 μg / ml. Afterwards, cells were harvested at each time point and lysed with RIPA buffer (Thermo Fisher Scientific, 89900) containing 1x protease inhibitor cocktail (Sigma-Aldrich, 4693132001) on ice for 20 min, followed by centrifugation at 16,500 × g for 20 min at 4°C, and the supernatant was collected. Protein concentration in the supernatant was measured by Bradford assay (Bio-Rad, 5000006), and equal amounts of proteins were separated by SDS-PAGE and immunoblotted with the corresponding antibodies. Quantification of immunoblotting data was performed by GelQuant.NET (BiochemLabSolutions) and normalized to α-tubulin. In addition, POMC incubated with or without MG132 (10 μM) for 8 h ha and / or Marchf6 3f POMC in HEK293T cells co-expressing ha and Marchf6 3f Immunoblot analysis was performed. In addition, for ubiquitination analysis, HEK293T cells were treated with POMC myc , ha Ub, and Marchf6 3f or Marchf6 3f P460AAfter transfection with and incubation for 48 h, cells were treated with or without 10 μM MG132 for 8 h. Afterwards, cells were lysed with lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1% NP-40, pH 7.6) containing 10 μM NEM (N-ethylmaleimide) (Sigma-Aldrich, E3876) and 1x protease inhibitor cocktail, and the supernatant was immunoprecipitated with magnetic bead-conjugated rabbit anti-myc (GeneTex, GTX29106). The bound proteins were eluted from the magnetic beads with 2X SDS sample buffer, the sample was heated at 95 °C for 5 minutes, and the eluted proteins were separated using SDS-PAGE and immunoblotted with the corresponding antibodies.
[0268] CHX-tracking analysis results, exogenous POMC ha While it was short-lived in WT HEK293T (human embryonic kidney) cells, it was markedly stabilized in Marchf6-KO cells (Fig. 3A and B). Endogenous POMC was also short-lived in N43 / 5 (mouse embryonic hypothalamus) cells, but was markedly stabilized in Marchf6-KO N43 / 5 cells (Fig. 3C). Furthermore, the endogenous POMC stabilized in Marchf6-KO N43 / 5 cells was found to be shortened when Marchf63f tagged with three flags at the C-terminus of WT Marchf6 was expressed, and Marchf6 with mutations introduced into the region interacting with POMC 3f P460A It was found that POMC degradation did not occur during the expression of Marchf6, and SM (squalene monooxygenase), known as a substrate of Marchf6, was not degraded by Marchf6. 3fP460A It was shown that degradation occurred even when POMC was expressed (Fig. 2F), confirming that Marchf6 degrades POMC by directly binding to the P460 region of Marchf6.
[0269] Also, POMC ha and Marchf6 3f Immunoblot analysis results of Marchf6 3f and POMC ha POMC by co-expression of ha The level of POMC was found to be decreased, which was restored by treatment with MG132, a proteasome inhibitor (Fig. 2G). ha It was confirmed that the degradation was proteasome dependent.
[0270] Also, ha POMC with Ub (N-terminally ha-tagged Ub) myc Ubiquitination analysis in cells expressing POMC (C-terminally myc-tagged POMC) revealed polyubiquitinated POMC. myc Go Marchf6 3f Marchf6, which is inaccessible to POMC, was increased by co-expression with 3f P460 or catalytically inactive Marchf6 3f C9A This was not the case when co-expressed (Fig. 2H and Fig. 3D).
[0271]
[0272] 3-2. Confirmation of the correlation between POMC decomposition and the ERpQC pathway.
[0273] To determine whether the stress-induced pre-emptive protein quality control (ERpQC) pathway is involved in Marchf6-mediated POMC degradation, HEK293T cells were transfected with 15 nM of siRNAs against Bag6 (chaperone), Derl1 (ER recruiting factor) and VCP (a valosincontaining AAA+-ATPase; also known as p97), which are key components of ERpQC (Bag6: SCBT, 15 sc72614; Derl1: SCBT, sc-60519; VCP: SCBT, sc-37187) using Lipofectamine RNAiMAX (Thermo Fisher Scientific, 13778150), and incubated for 24 h. After transfection, 0.5 μg / ml of pCH4129 (POMC ha ) were transfected with Lipofectamine 2000 (Thermo Fisher Scientific, 11668019) and incubated for 24 h. Afterwards, CHX-chase analysis was performed.
[0274] As a result, genes in the ERpQC pathway knocked down with siRNA did not affect the level of POMC mRNA (Fig. 3F). ha , which was shown to stabilize (Fig. 3E), confirming that the ERpQC pathway is positively involved in the degradation of cytoplasmically-exposed POMC.
[0275]
[0276] Example 4. POMC target site specificity of Marchf6
[0277] To clarify the POMC domain that binds to the C4 domain of Marchf6, Y2H analysis was performed using a set of POMC fragments in which the C4 of Marchf6 and the C-terminus (Ct-) of POMC were truncated. For this purpose, pCH4540 (C4), pCH4132 (POMC), or its truncated form pCH4235 (POMC 1-76 ), pCH4236 (POMC 1-87 ), pCH4237 (POMC 1-102 ), pCH4238 (POMC 1-137 ) and pCH4239 (POMC 1-176 ) were co-transformed into CHY726 and spotted and analyzed on SC(-Leu / -Trp) or SC(-Leu / -Trp / -His) plates as in the above examples. In addition, for the analysis of the interaction between full-length Marchf6 and POMC, pCH836 (Marchf6) or pCH4311 (Marchf6) were co-transformed into S. cerevisiae CHY712. P460A ) as bait, pCH4203 (POMC 1-267 ), pCH4204 (POMC 77-267 ) or pCH4313 (POMC 1-76 ) was transformed as prey and split-Ub analysis was performed. In addition, for GST (Glutathione-S-transferase) pull-down analysis, purified GST, GST-POMC 1-76 , GST-POMC 27-76 or GST-POMC 1-26 50 μg was incubated with 50 μl of glutathione Sepharose beads (Cytiva, 17-0756-05) at 4°C for 2 hours.
[0278] pCH879 (Marchf6 3f) transfected HEK293T cells were lysed with lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1% NP-40, pH 7.6) containing 1X protease inhibitor cocktail. The extracts and the beads were further incubated at 4°C for 2 hours, and then washed three times with 0.5 ml of GST-wash buffer (20 mM Tris-HCl, 137 mM NaCl, 2 mM EDTA, 0.5% NP-40, 10% glycerol, pH 7.6). The proteins bound to the beads were eluted with 2X SDS-sample buffer, heated at 37°C for 20 minutes to perform SDS-PAGE, Coomassie blue staining, and immunoblotting using anti-flag antibody.
[0279] Analysis of the POMC recognition site by Marchf6 using Y2H revealed that the C4 region of Marchf6 is a POMC domain containing the signal peptide (SP) and the Nt-segment of N-POMC (Nt-POMC domain). 1-76 was shown to interact with POMC (Fig. 4A). In addition, split-Ub analysis results showed that Marchf6 interacts with POMC 1-267 and POMC 1-76 Interact with and POMC 77-267 It was found that Marchf6 did not interact with GST (Fig. 4B). In addition, GST pull-down analysis results showed that Marchf6 3f GST-POMC 1-76 Directly binds to GST-POMC 27-76 It was shown to bind very weakly to GSTPOMC 1-26 It was found that Marchf6 hardly binds to the degron (Fig. 4C). This confirmed that Marchf6 recognizes the degron that contains SP and is adjacent to the Nt-POMC segment.
[0280]
[0281] Example 5. Regulation of POMC translocation to the ER by Marchf6
[0282] 5-1. Production of POMC-specific antibodies including SP
[0283] To produce an antibody specific for SP-containing POMC, a peptide (SEQ ID NO: 1) of QASMEVRGWC (Q, Gln; A, Ala; S, Ser; M, Met; E, Glu; V, Val; R, Arg; W, Trp; and C, Cys) corresponding to positions 19 to 28 of human POMC was synthesized as an epitope (Fig. 4D), and rabbit polyclonal antisera against SP-containing POMC-derived peptides were produced by AbClon (Seoul, South Korea). Subsequently, pre-conjugated GST-POMC 27-76 Antibodies specific for SP-containing POMC were “negatively” selected from 1 ml of Affi-Gel 10 / 15 beads containing 1.5 mg of GST-POMC and 1 ml of antiserum incubated overnight at 4°C, and the flow-through fraction was purified by pre-conjugating GST-POMC. 1-76 The beads were further incubated with 1 ml of Affi-Gel 10 / 15 beads containing 1 mg of POMC overnight at 4°C. The beads were then washed at least five times with 10 ml of ice-cold PBS, and the antibody bound to the beads was eluted with 1 ml of 0.1 M glycine-HCl (pH 3.0). The eluted fractions were immediately neutralized with 1 M Tris (pH 8.0) and concentrated by protein A-Sepharose chromatography (Amicogen, Korea), producing antibodies specific for SP-containing POMC and anti-POMC. SP (anti-POMC SP ) was named as an antibody. To confirm whether the antibody produced in this way can detect POMC containing SP, GST-POMC 1-76 , GST-POMC27-76 (SP not included) and GST-POMC 1-26 Immunoblot analysis was performed using (including SP).
[0284] As a result, anti-POMC SP Antibody is GST-POMC containing SP 1-76 and GST-POMC 1-26 was specifically detected, but GST-POMC without SP 27-76 was found not to be recognized (Fig. 4E).
[0285]
[0286] 5-2. Confirmation of regulation of POMC intracellular movement by Marchf6
[0287] To confirm the degradation of POMC by Marchf6 and its subsequent subcellular localization, pCH4129 (POMC) was transfected into WT HEK293T cells or Marchf6-KO HEK293T cells. ha), the cells were treated with MG132 (10 μM) for 8 h in the presence or absence of Eeyarestatin I (8 μM), an ER translocation inhibitor, and then subjected to subcellular fractionation followed by immunoprecipitation (IP)-immunoblotting (IB) analysis for cytosol-organelle fractionation assay (Fig. 4F). Specifically, cells were washed with PBS, treated with semi-permeabilization buffer (110 mM KOAc, 50 mM HEPES, 2 mM MgCl2, 1 mM benzamidine, 0.01% digitonin, pH 7.4) containing 1X protease inhibitor cocktail on ice for 5 min, and centrifuged at 500×g for 10 min at 4°C to obtain the supernatant as the cytosolic fraction. After that, the cells after separating the supernatant were washed with cold PBS to remove the residual digitonin extract, and disrupted with IP buffer (50 mM HEPES, 150 mM NaCl, 1% Triton X-100, pH 7.4) containing 1X protease inhibitor cocktail on ice for 10 minutes. After disruption, the cells were centrifuged at 12,000 × g for 10 minutes at 4°C, and the supernatant was obtained as an organelle fraction. The cytoplasm and organelle fractions were incubated with anti-POMCSP antibody (1:2,000) prepared in Example 5-1 above at 4°C overnight, and Dynabeads Protein G (Thermo Fisher Scientific, 10004D) was added and incubated for an additional 90 minutes at 4°C. To remove nonspecifically bound or unbound proteins, wash with IP washing solution (50 mM HEPES, 150 mM NaCl, 0.5% Triton X-100, pH 7.0) for 5 min at 4°C.4) Washed three times, the immunoprecipitated proteins were eluted with 2x SDS-sample buffer, heated at 95°C for 5 minutes, subjected to SDS-PAGE, and immunoblotting analysis was performed using anti-ha.
[0288] As a result, POMC containing SP ha was detected in the cytosolic fraction of Marchf6-KO HEK293T cells, but not in wild-type cells (Fig. 4G, cf. lanes 5 and 7). In particular, when treated with EerI, an ER trafficking inhibitor, SP-containing POMC ha Not only did it increase the prohormone in the cytosolic fraction (digitonin-extracted) of Marchf6-KO HEK293T cells, it also made the prohormone detectable in wild-type cells (Fig. 4G, lanes 5 to ).
[0289] These results confirm that Marchf6 positively regulates the translocation and degradation of early POMC to the ER.
[0290]
[0291] Example 6. Confirmation of the POMC-induced ER stress and ferroptosis inhibition effect of Marchf6.
[0292] 6-1. ER stress and ferroptosis induced by excessive POMC
[0293] To understand the functional or mechanistic link between Marchf6-mediated POMC degradation and ferroptosis, we used C11-BODIPY, a lipid peroxidation sensor. 581 / 591 Using POMC ha Lipid ROS levels were compared in N43 / 5 cells overexpressing pCH4129 (POMC). Specifically, pCH4129 (POMC) was transfected into WT or Marchf6-KO N43 / 5 cells. ha ) were transfected for 48 hours and 2 μM C11-BODIPY 581 / 591(Thermo Fisher Scientific, D3861). After incubation at 37°C for 30 min, the fluorescent probe-treated cells were trypsinized, transferred to a 15 ml Falcon tube, washed three times with 1 ml of ice-cold PBS, and then transferred to an ice-cold round-bottom polystyrene tube (Corning, 352235). The amount of lipid ROS in ~20,000 cells was measured by CytoFLEX LX (Beckman Coulter) using fluorescein isothiocyanate (FITC) and analyzed with FlowJo v10.8.1 (BD Bioscience). In addition, cell viability was analyzed using the CellTiter-Glo luminescent 3D cell viability assay kit (Promega, G9241) and a multimode plate reader (TECAN, Spark 10M). At this time, when evaluating cell death inhibition, pCH60 (empty vector) or pCH4129 (POMC ha ) (final concentration of 1 μg / ml each) were treated with 5 μM Fer-1, 20 μM Z-VAD-FMK, or 40 μM Nec-1, cultured for 24 h, and cell viability was analyzed. Intracellular NADP(H) levels were measured using the NADP / NADPH-Glo assay kit (Promega, G9081) and a multimode plate reader (TECAN, Spark 10M). In addition, LDH activity was measured using the Cytotoxicity Detection Kit Plus (LDH) (Sigma, 4744926001).
[0294] Lipid peroxidation assay results showed that POMC was expressed in N43 / 5 cells. haLipid peroxidation increased with increasing levels of POMC (Fig. 5A), and the level of NADP(H), a biomarker that can predict ferroptosis, decreased (Fig. 5B). In addition, POMC ha As the level of POMC increased, cell viability gradually decreased (Fig. 5C). ha This dose-dependent lethality was further confirmed by assessing the release of lactate dehydrogenase (LDH) (Fig. 5D). In addition, the expression levels of ferroptosis-related proteins, Gpx4, CHOP, Nox2, and Nox4, were analyzed by immunoblotting, and POMC ha As the level of POMC increased, the expression level of Gpx4 (glutathione peroxidase 4), a key regulator of ferroptosis, was found to decrease, and the levels of CHOP (a C / EBP homologous transcription factor), an ER stress marker, and Nox2 and Nox4, ROS-generating NADPH oxidases, were also found to increase (Fig. 5E and Fig. 8A). In addition, POMC ha Overexpression of also significantly increased the level of 4-hydroxynonenal (4HNE), a lipid peroxidation marker, which was restored by treatment with Fer-1, a lipid peroxide scavenger (Fig. 5F).
[0295] Through this, we confirmed that overloaded POMC induces ferroptosis by downregulating Gpx4 and upregulating CHOP, Nox2, and Nox4, thereby increasing lipid peroxidation.
[0296]
[0297] 6-2. Inhibition of POMC-induced ferroptosis by Marchf6
[0298] As Marchf6 mediates the degradation of POMC, it was expected that loss of Marchf6 would render POMC neurons hypersensitive to POMC-induced ferroptosis, and pCH60 (empty vector), pCH879 (Marchf6 3f ), pCH880 (Marchf6 flag C9A ) or pCH4170 (Marchf6 flag P460A ) was transfected into WT or Marchf6-KO N43 / 5 cells, and the degree of ferroptosis induction in POMC neurons was analyzed as in Example 6-1 above.
[0299] As a result, POMC is absent when Marchf6 is ha -The survival rate of overexpressing N43 / 5 cells was significantly reduced, which was comparable to that of WT Marchf6 3f recovered by ectopic expression of catalytically inactive Marchf6 3f C9A and POMC inaccessible Marchf6 3f P460A It was found that it was not recovered by (Figs. 5G and 5H). In addition, POMC ha -Decreased expression levels of Gpx4, CHOP, Nox2, and Nox4 proteins in overexpressed Marchf6-KO N43 / 5 cells 3f It was recovered by Marchf6 3f C9A and Marchf6 3f P460A It was found that it was not recovered by (Fig. 5I). In addition, POMC ha- The reduced viability of overexpressing Marchf6-KO N43 / 5 cells was restored by treatment with the ferroptosis inhibitor Fer-1 (ferrostatin-1), but not by treatment with the apoptosis inhibitor Z-VAD (Z-VAD-FMK) or Nec-1 (necroptosis inhibitor necrostatin-1) (Fig. 5J).
[0300] Through this, we confirmed that Marchf6 inhibits ferroptosis in POMC neuronal cells by specifically promoting POMC degradation.
[0301]
[0302] 6-3. Induction of ferroptosis and ER stress by cytoplasmic residual POMC
[0303] To determine the biological impact of POMC remaining in the cytoplasm due to its non-degradation by Marchf6, POMC remaining / maintained in the cytoplasm due to the absence of ER-targeting SP Δ1-26 We expressed N43 / 5 POMC neurons and analyzed their cell viability, lipid peroxidation, NADP(H) content, LDH release, expression levels of Gpx4, CHOP, Nox2 and Nox4, expression of ER stress marker CHOP, and expression and activation levels of ER stress sensors PERK (protein kinase RNA-like ER kinase), Ire1 (inositol requiring protein-1) and Atf6 (activating transcription factor-6).
[0304] As a result, POMC without SP ha Δ1-26 POMC containing SP ha(FL, Full length) showed a greater effect on lipid peroxidation, NADP(H) content, LDH release, and cell viability compared to POMC (Fig. 6A to D). In addition, cytoplasmic POMC in N43 / 5 cells ha Δ1-26 The expression of POMC on the battlefield ha Compared to the case where POMC was expressed, the levels of CHOP, Nox2, and Nox4 were significantly increased, and the level of Gpx4 was significantly decreased (Fig. 6E). In addition, cytoplasmic POMC ha Δ1-26 POMC up-regulated the expression of CHOP, an ER stress marker, and analyzed the activation of upstream components of the signaling pathway related to it, such as eIF2α (a eukaryotic initiation factor), PERK, Ire1, and Atf6, through expression and phosphorylation. ha or POMC ha Δ1-26 Overexpression of POMC increased the phosphorylation of PERK and eIF2α, upregulated Atf4, but did not affect Ire1 and Atf6 (Fig. 6E), confirming that POMC remaining in the cytoplasm induces ER stress response through the PERK / eIF2α / Atf4 / CHOP signaling pathway.
[0305]
[0306] Example 7. Analysis of the ER stress and ferroptosis-inducing mechanisms of cytoplasmic POMC.
[0307] 7-1. Gpx4 degradation through chaperone-mediated autophagy
[0308] POMC on the battlefield ha or cytoplasmic POMC ha Δ1-26 To determine whether this modulates the expression of Gpx4 protein, which is known to be degraded by ferroptosis induction, POMC in the whole body ha or cytoplasmic POMC haΔ1-26 The mRNA level of Gpx4 was analyzed by qRT-PCR in N43 / 5 cells overexpressing POMC, and CHX-chase analysis was performed. In addition, Gpx4 degradation occurs through chaperone-mediated autophagy (CMA), macroautophagy, or the Ub-proteasome system, so POMC ha Δ1-26 N43 / 5 cells overexpressing POMC were treated with lysosomal inhibitors such as chloroquine (CQ) or BafA1 (bafilomycin A1), proteasome inhibitor MG132, or macroautophagy inhibitor 3-MA (3-methyladenine), and the expression of Gpx4 protein was analyzed by immunoblotting. In addition, POMC ha Δ1-26 The expression of Lamp2a (lysosome-associated protein 2A), heat shock chaperones Hsc70 and Hsp90 was confirmed by immunoblotting in N43 / 5 cells overexpressing Lamp2a, and the change in Gpx4 by treatment with Lamp2a-specific siRNA (SCBT, sc-35791) was analyzed.
[0309] As a result, the battlefield POMC ha and cytoplasmic POMC ha Δ1-26 Expression of downregulated the protein expression without affecting the mRNA level of Gpx4, and in particular, POMC remaining in the cytoplasm ha Δ1-26 ER-Mobile POMC ha Compared to POMC, POMC significantly down-regulated Gpx4 (Fig. 6E and F), confirming that POMC can induce Gpx4 degradation in the cytoplasm. In addition, CHX-tracking experiments showed that cytoplasmic POMC ha Δ1-26was found to accelerate the degradation of Gpx4 (Fig. 6G). In addition, POMC ha Δ1-26 -Gpx4 downregulation in N43 / 5 cells expressing POMC was restored by treatment with CQ and BafA1, unlike when treated with MG132 and 3-MA (Fig. 6H), confirming that POMC-induced Gpx4 degradation is related to CMA (Fig. 6I). Indeed, POMC ha Δ1-26 Expression of CMA significantly increased the levels of CMA components such as Lamp2a, Hsc70, and Hsp90 (Fig. 6J), and knockdown of the CMA receptor Lamp2a significantly stabilized Gpx4 protein (Fig. 6K).
[0310]
[0311] 7-2. Reduced Hspa5-Gpx4 interaction
[0312] Since the stress-inducible heat shock factor Hspa5 (known as the major ER chaperone BiP or Grp78) is known to inhibit the degradation of Gpx4 through direct interaction with Gpx4 during ferroptosis, this was confirmed in ferroptosis due to cytoplasmic retention of POMC. Specifically, N43 / 5 cells were transfected with 10 nM of Hspa5-specific siRNA (SCBT, sc-35522) using Lipofectamine RNAiMAX (Thermo Fisher Scientific, 13778150), and 24 h later, pCH4134 (POMC ha Δ1-26) (final 1 μg / ml) was transfected with Lipofectamine 2000 (Thermo Fisher Scientific, 11668019), and then the mRNA level of Gpx4 was analyzed and CHX-chase assay was performed. In addition, to confirm whether Hspa5 counteracts POMC-induced ferroptosis in the cytoplasm, Hspa5 remaining in the cytoplasm in the absence of SP myc Δ1-18 and POMC ha Δ1-26 were co-expressed in N43 / 5 cells, and a ferroptosis induction assay was performed as in Example 6-1. In addition, a cytosol-organelle fractionation assay was performed as in Example 5-2. In addition, a coimmunoprecipitation assay was performed to confirm whether POMC maintained in the cytoplasm promotes Gpx4 degradation by interfering with the Hspa5-Gpx4 interaction.
[0313] CHX-tracking analysis results, POMC ha Δ1-26 - Knockdown of Hspa5 in POMC-expressing N43 / 5 cells accelerated the degradation of Gpx4 without affecting Gpx4 mRNA (Fig. 7A and B). In addition, ha Δ1-26 Lipid peroxidation and decreased cell viability by Hspa5 myc Δ1-18 Co-expression of Hspa5 was improved (Fig. 8B and C). myc Δ1-18 and POMC ha Δ1-26 Co-expression of POMC ha Δ1-26 The changes in the expression levels of Gpx4, CHOP, Nox2, and Nox4 induced by POMC were restored (Fig. 8D). ha Δ1-26 Degradation of Gpx4 by Hspa5myc Δ1-18 Co-expression with Hspa5 was shown to inhibit POMC-mediated ferroptosis (Fig. 8E). This suggests that cytoplasmic Hspa5 inhibits POMC-mediated ferroptosis by preventing the degradation of Gpx4 and upregulating ER stress markers. In addition, cytoplasmic-organelle fractionation analysis revealed that POMC ha Δ1-26 -Hspa5 was significantly detected in the Triton X-100-treated organelle fraction (Fig. 7C, lanes 5 and 6) as well as in the digitonin-treated cytosolic fraction (Fig. 7, lanes 3 and 4) of N43 / 5 cells expressing POMC. In addition, ha Δ1-26 Expression of markedly increased the levels of Hspa5 as an indicator of ER stress response, whereas cytoplasmic POMC ha Δ1-26 Expression of POMC was found to significantly reduce the level of Gpx4, particularly in the cytoplasmic fraction (Fig. 7C, lanes 3 and 4). In addition, co-immunoprecipitation analysis revealed that POMC ha Δ1-26 Go Hspa5 myc It was shown that POMC, which was unable to move from the cytoplasm to the ER, induces the degradation of Gpx4 by sequestering Hspa5 (Fig. 7D and E), thereby reducing the interaction between Gpx4 and Hspa5.
[0314]
[0315] Example 8. Analysis of the POMC transport mechanism of Marchf6 to the ER.
[0316] POMC on the battlefield haSince Marchf6 knockdown significantly reduced the Hspa5-Gpx4 interaction in Marchf6-KO N43 / 5 cells (Fig. 7F, cf. lanes 2 and 3), and this reduction was restored by Fer-1 treatment (Fig. 7F, cf. lane 4), we examined whether Marchf6 knockdown affected the ER trafficking of SP-containing (ER-mobile) POMC by increasing lipid ROS levels by differential detergent subcellular fractionation followed by IP-IB analysis.
[0317] As a result, POMC in the cytosolic fraction (digitonin-extracted) of Marchf6-KO N43 / 5 cells ha While the level of POMC was significantly reduced by Fer-1 treatment (Fig. 7G, cf. lanes 3 and 4), POMC was not significantly reduced even in the cytosolic fraction of WT N43 / 5 cells when treated with erastin, a ferroptosis inducer. ha The level was found to increase significantly (Fig. 7H, cf. lanes 3 and 4).
[0318] Since erastin upregulates lipid peroxidation and induces Marchf6 inactivation, these results suggest that Marchf6 promotes POMC translocation to the ER by preventing lipid peroxidation.
[0319]
[0320] Example 9. Analysis of the physiological role of POMC neuron-specific Marchf6-mediated POMC degradation.
[0321] To determine the physiological role of Marchf6-mediated POMC degradation in POMC neurons, we generated POMC neuron-specific Marchf6 deficiency mice (Marchf6) using Cre-loxP technology. POMC) was produced. Specifically, Marchf6 without LacZ and neomycin selection cassette in C57BL / 6J background fl / fl POMC neuron-specific Marchf6-floxed mice were generated by crossing mice (EUCOMM, Marchf6tm1c) with POMC-Cre mice (Jackson Laboratory, #JAX010714). Genomic DNA obtained from tail samples of the generated mice was analyzed by PCR-based genotyping. The genotyping primer pairs used here (OCH5339: CACTAGACATGCTGTCAACGTGAGTATTA, OCH9075: TCAAGTAATAAGATTAAATACATGAGCCAGGC; and OCH5339: CACTAGACATGCTGTCAACGTGAGTATTA, OCH9129: GCGAGCTCAGACCATAACTTCG) were designed to detect 277-bp wild-type DNA of Marchf6 exon 5 and its 248-bp floxed DNA, respectively. We generated POMC neuron-specific Marchf6-deficient mice (Marchf6 POMC) were measured using a digital scale during the week, and body composition such as fat mass and lean mass were measured using a quantitative NMR-based analyzer (EchoMRI, EchoMRI-700). To assess energy expenditures, animals were acclimated to the assay conditions for 48 h prior to the assay and then assessed using PhenoMaster (TSE SYSTEM) for an additional 48 h under a 12:12 h day / night cycle. The day / night cycle during this assay was identical to that during the initial housing of the mice, and the same food was provided in single metabolic cages. Additionally, for immunohistochemistry (IHC) analysis, mice were anesthetized by intraperitoneal injection of Avertin (250 mg / kg of body weight, Sigma, T48402) and transcardially perfused sequentially with phosphate-buffered saline (PBS) and 4% paraformaldehyde (PFA) (Mentos Biotechnology, M1177). Brains were removed from the mice and post-fixed in 4% PFA solution at 4°C for subsequent sectioning (coronal sections at 60 μm thickness) using a vibratome (Leica, VT1000S). Arcuate nucleus (ARC)-containing tissue sections were obtained according to the mouse brain atlas (https: / mouse.brain-map.org / static / atlas) and incubated with blocking buffer solution (100 mM phosphate buffer, 4% normal donkey serum, 0.5% Triton X-100) for 30 min at 4°C.Afterwards, the tissues were treated with primary antibodies anti-Gpx4 (1:500), anti-4HNE (1:500), and anti-Hspa5 (1:500) at 4°C for 12 h, and washed three times with 100 mM phosphate buffer at 4°C for 10 min each, and treated with Alexa-Fluor 488, 568, or 647-conjugated secondary antibodies (1:500) corresponding to each primary antibody at 4°C for 12 h. The tissues were mounted with mounting solution containing DAPI (Vector Laboratories, H-2000) and imaged with a laser scanning confocal microscope (Olympus, FV1000) at a resolution of 1024 × 1024 pixels, and the fluorescence intensity was quantified using ImageJ (NIH). In addition, Marchf6. POMC To measure the level of POMC-derived α-MSH (α-melanocyte stimulating hormone) in the mouse hypothalamus, the hypothalamus was collected from the mouse, immediately frozen in liquid nitrogen, and stored at -80°C. The frozen hypothalamus was pulverized, resuspended in 0.1 N HCl solution, and sonicated. The supernatant was centrifuged at 17,000 × g for 20 min at 4°C, and ELISA analysis was performed using an α-MSH ELISA kit (Phoenix Pharmaceuticals, EK-04301).
[0322] Marchf6, a POMC neuron-specific Marchf6-deficient mouse POMC Both male and female mice were normal at birth, but under normal diet, littermates Marchf6 fl / fl A significant increase in body weight was observed in mice compared to mice aged 20 weeks (Figs. 9A and B and 10A and B). In particular, the total amount of food consumed was significantly higher in Marchf6 mice aged 20 weeks. fl / fl Marchf6 compared to mouse POMCwas found to be significantly higher in mice (Fig. 9C and D). In addition, body composition analysis results showed that Marchf6 POMC Both male and female mice showed increased fat mass and decreased lean body mass (Fig. 10C to F). In contrast, energy expenditure was significantly higher in Marchf6 mice compared to littermates. fl / fl Marchf6 compared to mouse POMC was found to be significantly reduced in mice (Fig. 9E and F). In addition, IHC analysis showed that Marchf6 in littermates fl / fl Marchf6 compared to mouse POMC Levels of lipid peroxidation products, 4-HNE, POMC, and Hspa5, were markedly increased in the hypothalamic ARC of male mice (Figs. 9G and H, and 11), whereas Gpx4 levels were markedly reduced in Marchf6-deficient POMC neurons (Figs. 9I and 11). In addition, Marchf6 POMC Levels of POMC-derived α-MSH in the hypothalamus of mice are elevated by Marchf6 fl / fl It was significantly reduced compared to mice (Fig. 9J). Marchf6 POMC Mouse is Marchf6 of the same age fl / fl Because POMC protein levels are higher in POMC neurons than in mice, increased lipid peroxidation induced by Marchf6 deletion may delay POMC transport to the ER, resulting in reduced release of α-MSH, one of the POMC-derived bioactive peptides.
[0323] These results demonstrate that POMC neuron-specific Marchf6-deficient mice exhibit hyperphagia, weight gain, and reduced energy expenditure due to increased POMC-mediated ferroptosis damage, increased ER stress, and subsequent reduction in mature POMC-derived hormones.
Claims
1. An antigen peptide for producing an antibody specific for POMC (pro-opiomelanocortin), comprising the amino acid sequence of sequence number 1.
2. An antigen peptide for producing an antibody specific for POMC containing an SP (signal peptide) sequence according to claim 1.
3. A composition for producing an antibody specific for POMC, comprising the antigen peptide of paragraph 1.
4. A kit for producing an antibody specific for POMC, comprising the antigen peptide of paragraph 1. 5.a) A step of inducing an immune response by inoculating multiple times the antigen peptide of paragraph 1 or the composition of paragraph 3 into a host other than a human; and b) A method for producing an antibody specific for POMC, comprising the step of obtaining serum from the blood of a host.
6. A method for producing an antibody specific to POMC, further comprising a step of purifying an antibody specific to POMC from serum, in accordance with claim 5.
7. An antibody or antigen-binding fragment specific for POMC that specifically binds to POMC manufactured by the method of Article 5.
8. An antibody or antigen-binding fragment specific for POMC that specifically binds to POMC comprising an SP sequence, according to claim 7.
9. In the 7th paragraph, the antibody is a polyclonal antibody, an antibody or antigen-binding fragment specific for POMC.
10. An antibody or antigen-binding fragment specific for POMC that binds to an epitope or epitope segment comprising the amino acid sequence of sequence number 1 in claim 7.
11. In claim 7, an antibody or antigen-binding fragment specific for POMC that specifically binds to POMC present in the cytoplasm of POMC neurons.
12. A pharmaceutical composition for preventing or treating a disease related to POMC accumulation, comprising an antibody or antigen-binding fragment specific for POMC of Article 7 as an active ingredient.
13. A pharmaceutical composition for preventing or treating a POMC accumulation-related disease, which is a disease in which POMC accumulates in the cytoplasm of POMC neurons, according to claim 12.
14. A pharmaceutical composition for the prevention or treatment of a POMC accumulation-related disease, which is a metabolic disease, according to claim 12.
15. A pharmaceutical composition for preventing or treating a disease related to POMC accumulation, wherein the metabolic disease in claim 14 is any one selected from the group consisting of obesity, bulimia, diabetes, arteriosclerosis, hypertension, hyperlipidemia, fatty liver, metabolic liver disease, and cardiovascular disease.
16. A pharmaceutical composition for preventing or treating a disease related to Marchf6 (membrane associated ring-CH-type finger 6) dysfunction, comprising an antibody or antigen-binding fragment specific for POMC of Article 7 as an active ingredient.
17. A pharmaceutical composition for preventing or treating a disease related to Marchf6 dysfunction, which is a disease in which the function of Marchf6, which decomposes the SP sequence of cytoplasmic POMC, is reduced in accordance with claim 16.
18. A composition for diagnosing a disease related to POMC accumulation, comprising an antibody or antigen-binding fragment specific for POMC of Article 7 as an active ingredient.
19. A composition for diagnosing a disease related to Marchf6 dysfunction, comprising an antibody or antigen-binding fragment specific for POMC of Article 7 as an active ingredient.
20. A method for providing information for diagnosing a metabolic disease, comprising detecting POMC accumulated in the cytoplasm of POMC neurons in a biological sample isolated from a subject using an antibody or antigen-binding fragment specific for POMC of Article 7.
21. A method for providing information for diagnosing a metabolic disease, wherein the metabolic disease in paragraph 20 is any one selected from the group consisting of obesity, bulimia, diabetes, arteriosclerosis, hypertension, hyperlipidemia, fatty liver, metabolic liver disease, and cardiovascular disease.
22. A method for preventing or treating a disease related to Marchf6 (membrane associated ring-CH-type finger 6) dysfunction, comprising administering to a subject a pharmaceutically effective amount of the pharmaceutical composition of claim 16.
23. A pharmaceutical composition for preventing or treating a metabolic disease, comprising Marchf6 (membrane associated ring-CH-type finger 6) protein or a fragment thereof, or an activator or expression promoter of Marchf6 as an active ingredient.
24. A pharmaceutical composition for preventing or treating a metabolic disease, wherein the fragment of Marchf6 comprises a C4 region in claim 23.
25. A pharmaceutical composition for preventing or treating a metabolic disease, wherein the fragment of Marchf6 comprises C9 and P460 in the amino acid sequence of claim 23.
26. A pharmaceutical composition for preventing or treating a metabolic disease, wherein the expression promoter is a recombinant vector containing a nucleic acid encoding Marchf6 or a fragment thereof in claim 23.
27. A pharmaceutical composition for preventing or treating a metabolic disease, wherein the metabolic disease is any one selected from the group consisting of obesity, bulimia, diabetes, arteriosclerosis, hypertension, hyperlipidemia, fatty liver, metabolic liver disease, and cardiovascular disease.
28. A pharmaceutical composition for preventing or treating a metabolic disease, further comprising an activator or expression promoter of Bag6, Derl1 or VCP, according to claim 23.
29. A composition for promoting POMC (pro-opiomelanocortin) degradation, comprising a Marchf6 protein or a fragment thereof, or an activator or expression promoter of Marchf6.
30. A composition for promoting POMC decomposition, which promotes the decomposition of POMC in the cytoplasm of POMC neurons in claim 29.
31. A composition for promoting translocation to the ER, comprising a Marchf6 protein or a fragment thereof, or an activator or expression promoter of Marchf6.
32. A composition for inhibiting ER stress or ferroptosis in POMC neurons, comprising a Marchf6 protein or a fragment thereof, or an activator or expression promoter of Marchf6.
33. A composition for inhibiting ER stress or ferroptosis, which inhibits increased ER stress or ferroptosis caused by excessive POMC or cytoplasmic residual POMC in claim 32.
34. A food composition for preventing or improving metabolic diseases, comprising Marchf6 protein or a fragment thereof, or an activator or expression promoter of Marchf6 as an active ingredient. 35.A) A step of treating a candidate substance to cells separated from an object; B) a step of confirming the level of Marchf6 expression or activation in cells treated with the candidate substance; and C) A method for screening an obesity treatment agent, comprising a step of comparing the level of Marchf6 expression or activation with a control group.
36. A method for screening for an obesity treatment agent in claim 35, wherein the cell is a POMC neuron.
37. A method for preventing or treating a metabolic disease, comprising administering to a subject a pharmaceutical composition of claim 23 in a pharmaceutically effective amount.
Citation Information
Patent Citations
Affinity medicant conjugates
KR1020160142885A
Use of GPR101 receptor in methods to identify modulators of hypothalamic proopiomelanocortin (POMC)-derived biologically active peptide secretion useful in the treatment of POMC-derived biologically
US20100056442A1
Modulators of orphan nuclear receptors for NASH and other metabolic disorders
US20210052603A1
